NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT04988295,A Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non- Small Cell Lung Cancer After Osimertinib Failure,https://clinicaltrials.gov/study/NCT04988295,MARIPOSA-2,ACTIVE_NOT_RECRUITING,"The purpose of this study is to assess the efficacy of adding lazertinib to amivantamab, carboplatin, and pemetrexed (LACP/ACP-L dosing strategies) and amivantamab, carboplatin and pemetrexed (ACP) compared with carboplatin and pemetrexed (CP) in participants with locally advanced or metastatic epidermal growth factor receptor (EGFR) Exon 19del or Exon 21 L858R substitution non-small cell lung cancer (NSCLC) after osimertinib failure. The purpose of the extension cohort is to further describe the safety and efficacy for the ACP-L dosing schedule versus ACP with additional data. After completion of the primary analysis, the study may eventually transition to an open-label extension (OLE) or long-term extension (LTE) phase during which participants will have the option to continue their assigned treatment.",YES,"Carcinoma, Non-Small-Cell Lung",DRUG: Lazertinib|DRUG: Amivantamab|DRUG: Pemetrexed|DRUG: Carboplatin,"Main Study: Progression-free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Blinded Independent Central Review (BICR), PFS is defined as the time from randomization until the date of objective disease progression or death, whichever came first, as assessed by BICR according to RECIST version 1.1. Progressed disease: Sum of diameters increased by greater than or equal to (\>=)20 percent (%) and \>=5 millimeter (mm) from nadir (including baseline if it was smallest sum)., From randomization to either disease progression or death, whichever occurred first (up to 1 year 7 months)|Main Study + Extension Cohort: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs), Follow-up for the extension cohort is still ongoing and thus results from the analysis that includes the extension cohort will be reported up on study completion., up to 4 years 10 months|Main Study + Extension Cohort: Progression-free Survival (PFS) as Assessed by Blinded Independent Central Review, Up to 4 years 10 months","Main Study+ Extension Cohort: Objective Response Rate as Assessed by Blinded Independent Central Review, Up to 4 years 10 months|Main Study+ Extension Cohort: Overall Survival, Up to 4 years 10 months|Main Study+ Extension Cohort: Duration of Response as Assessed by Blinded Independent Central Review, Up to 4 years 10 months|Main Study+ Extension Cohort: Time to Subsequent Therapy, Up to 4 years 10 months|Main Study+ Extension Cohort: Progression-free Survival (PFS) After First Subsequent Therapy (PFS2), Up to 4 years 10 months|Main Study+ Extension Cohort: Time to Symptomatic Progression, Up to 4 years 10 months|Main Study+ Extension Cohort: Intracranial Progression-free Survival (PFS) as Assessed by Blinded Independent Central Review, Up to 4 years 10 months|Main Study: Number of Participants With Adverse Events (AEs), Up to 4 years 10 months|Main Study+ Extension Cohort: Number of Participants With Adverse Events (AEs) by Severity, Up to 4 years 10 months|Main Study+ Extension Cohort: Number of Participants With Clinical Laboratory Abnormalities, Up to 4 years 10 months|Main Study+ Extension Cohort: Serum Concentration of Amivantamab, Up to 4 years 10 months|Main Study+ Extension Cohort: Plasma Concentration of Lazertinib, Up to 4 years 10 months|Main Study + Extension Cohort: Number of Participants With Serum Anti-amivantamab Antibodies, Up to 4 years 10 months|Main Study+ Extension Cohort: Change From Baseline With Non-Small Cell Lung Cancer - Symptom Assessment Questionnaire (NSCLC-SAQ), Up to 4 years 10 months|Main Study+ Extension Cohort: Change From Baseline With European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC-QLQ-C30), Up to 4 years 10 months|Main Study+ Extension Cohort: Change From Baseline With Patient-Reported Outcomes Measurement Information System -Physical Function (PROMIS-PF), Up to 4 years 10 months",,"Janssen Research & Development, LLC",,ALL,"ADULT, OLDER_ADULT",PHASE3,776,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,CR109061|61186372NSC3002|2021-001825-33|2023-506518-33-00,2021-11-17,2023-07-10,2026-09-30,2021-08-03,2025-04-16,2025-04-16,"Southern Cancer Center, PC, Mobile, Alabama, 36608, United States|Arizona Oncology Associates, Tucson, Arizona, 85711, United States|City of Hope, Duarte, California, 91010, United States|Cedars Sinai Medical Center, Los Angeles, California, 90048, United States|University of California Irvine, Orange, California, 92868, United States|Rocky Mountain Cancer Centers, Colorado Springs, Colorado, 80907, United States|Holy Cross Hospital - Michael and Dianne Bienes Comprehensive Cancer Center, Fort Lauderdale, Florida, 33308, United States|University Cancer And Blood Center LLC, Athens, Georgia, 30607, United States|University of Mississippi Medical Center, Jackson, Mississippi, 39216, United States|Nebraska Cancer Specialists, Grand Island, Nebraska, 68803, United States|Astera Cancer Care, East Brunswick, New Jersey, 08816, United States|TriHealth Network, Cincinnati, Ohio, 45220, United States|Providence Portland Medical Center, Portland, Oregon, 97213, United States|Kaiser Permanente Northwest, Portland, Oregon, 97227, United States|Alliance Cancer Specialists, Horsham, Pennsylvania, 19044, United States|University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, 15232, United States|Baptist Cancer Center, Memphis, Tennessee, 38120, United States|Texas Oncology-Medical City Dallas, Dallas, Texas, 75230, United States|Texas Oncology Baylor Charles A Sammons Cancer Center, Dallas, Texas, 75246, United States|Texas Oncology, Grapevine, Texas, 76051, United States|Oncology Consultants Texas, Houston, Texas, 77030, United States|Texas Oncology - Northeast, Longview, Texas, 75601, United States|University of Vermont Medical Center, Burlington, Vermont, 05401, United States|University of Virginia, Charlottesville, Virginia, 22908, United States|Virginia Cancer Specialists, Fairfax, Virginia, 22031, United States|Blue Ridge Cancer Care, Wytheville, Virginia, 24382, United States|NorthWest Medical Specialties, PLLC, Puyallup, Washington, 98373, United States|Compass Oncology, Vancouver, Washington, 98684, United States|CINME Centro de Investigaciones Metabolicas, Caba, C1027AAP, Argentina|IADT Instituto Argentino de Diagnostico y Tratamiento, Caba, C1122, Argentina|Centro Medico Fleischer, Caba, C1414, Argentina|CEMIC (Centro de Educación Médica e Investigaciones Clínicas), Caba, C1431FWO, Argentina|Hospital Privado Universitario De Cordoba, Cordoba, X5016KEH, Argentina|Cemaic Centro Privado de Especialidades Medicas Ambulatorias e Investigacion Clinica, Córdoba, 5000, Argentina|Hospital Privado de la Comunidad, Mar del Plata, B7602CBM, Argentina|Clínica Viedma, Viedma, R8500ACE, Argentina|Grand Hopital De Charleroi Site Les Viviers, Charleroi, 6060, Belgium|UZA, Edegem, 2650, Belgium|UZ Gent, Gent, 9000, Belgium|Jessa Ziekenhuis - Campus Virga Jesse, Hasselt, 3500, Belgium|UZ Leuven, Leuven, 3000, Belgium|CHU Sart-Tilman, Liege, 4000, Belgium|Clinique Saint Pierre, Ottignies, 1340, Belgium|Cetus Oncologia, Belo Horizonte, 30110-017, Brazil|CIONC Centro Integrado de Oncologia de Curitiba, Curitiba, 80810 050, Brazil|Ynova Pesquisa Clinica, Florianopolis, 88020-210, Brazil|Fundação São Francisco Xavier, Ipatinga, 35162 189, Brazil|UPCO Unidade de Pesquisa Clinica em Oncologia, Pelotas, 96020 080, Brazil|Associacao Hospitalar Moinhos de Vento, Porto Alegre, 90035-001, Brazil|Hospital Ernesto Dornelles, Porto Alegre, 90160-093, Brazil|Oncoclinicas Rio de Janeiro S A, Rio de Janeiro, 22250-905, Brazil|Instituto D Or de Pesquisa e Ensino IDOR, Rio de Janeiro, 22281 100, Brazil|Instituto de Educacao, Pesquisa e Gestao em Saude Instituto Americas (COI), Rio de Janeiro, 22775 001, Brazil|Nucleo de Oncologia da Bahia, Salvador, 40170 110, Brazil|Hospital Sao Rafael, Salvador, 41253 190, Brazil|CEPHO Centro de Estudos e Pesquisa de Hematologia e Oncologia, Santo Andre, 09060 650, Brazil|Real e Benemerita Associacao Portuguesa de Beneficencia, Sao Paulo, 01323 900, Brazil|Hospital Paulistano, Sao Paulo, 01323-000, Brazil|Hospital Alemao Oswaldo Cruz, Sao Paulo, 01327 001, Brazil|Fundacao Antonio Prudente A C Camargo Cancer Center, Sao Paulo, 01509 900, Brazil|Onco Star SP Oncologia Ltda, Sao Paulo, 04543-000, Brazil|IOS - Instituto de Oncologia de Sorocaba Dr. Gilson Delgado, Sorocaba, 18030-005, Brazil|Hospital Nove de Julho, São Paulo, 01409902, Brazil|COT - Centro Oncologico do Triangulo S.A, Uberlandia, 38408-150, Brazil|Multifunctional Hospital for Active Treatment 'Serdika', Sofia, 1303, Bulgaria|Multiprofile Hospital for Active Treatment 'Tokuda Hospital Sofia', Sofia, 1407, Bulgaria|Specialized Hospital for Active Treatment in Oncology, Sofia, 1756, Bulgaria|UMHAT Sofia Med, Sofia, 1797, Bulgaria|Arthur J E Child Comprehensive Cancer Centre, Calgary, Alberta, T2N 5G2, Canada|British Columbia Cancer Agency, Vancouver, British Columbia, V5Z 4E6, Canada|McGill University Health Centre, Montreal, Quebec, H4A 3J1, Canada|Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, 100021, China|Peking University People s Hospital, Beijing, 100044, China|Beijing Cancer Hospital, Beijing, 100142, China|Chinese PLA General Hospital, Beijing, 100853, China|Beijing Chest hospital, Capital medical university, Beijing, 101199, China|Hunan Cancer hospital, Changsha, 410013, China|Sichuan Cancer Hospital, Chengdu, 610041, China|West China Hospital Sichuan University, Chengdu, 610041, China|Chongqing University Cancer Hospital, Chongqing, 400000, China|Southwest Hospital, ChongQing, 400038, China|The First Affiliated Hospital Sun Yat sen University, Guang Zhou, 510080, China|Sun Yat-Sen Memorial Hospital Sun Yat-sen University, Guangzhou, 510120, China|Zhejiang Cancer Hospital, Hang Zhou, 310022, China|Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, 310009, China|The Second Affiliated Hospital of Zhejiang University College of Medicine, Hangzhou, 310009, China|Sir Run Run Shaw Hospital Zhejiang University School of Medicine, Hangzhou, 310016, China|Harbin medical university cancer hospital, Harbin, 150000, China|Huizhou Municipal Central Hospital, Huizhou, 516001, China|Taizhou Hospital of Zhejiang Province, Linhai, 317000, China|Affiliated Hospital of North Sichuan Medical College, Nanchong, China|Ruijin Hospital Shanghai Jiao Tong University, Shanghai, 200025, China|Fudan University Shanghai Cancer Center, Shanghai, 200032, China|Shanghai East Hospital, Shanghai, 310000, China|Shenzhen university General Hospital, Shenzhen, 518055, China|Cancer Hospital Chinese Academy of Medical Sciences, Shenzhen, 518116, China|Tianjin Medical University General Hospital, Tianjin, 300052, China|Weifang People's Hospital, Weifang, 261000, China|The First Affiliated Hospital of Xian Jiaotong University, XI An, 710061, China|Yantai Yuhuangding Hospital, Yantai, 264000, China|Daping Hospital Army Characteristic Medical Center, Yuzhong District, 400042, China|Henan Cancer Hospital, Zhengzhou, 450008, China|Fakultni nemocnice Olomouc - I.P.Pavlova 6, Olomouc, 775 20, Czechia|Vitkovicka nemocnice a.s., Ostrava- Vitkovice, 70300, Czechia|Fakultni nemocnice Plzen, Plzen, 30599, Czechia|Rigshospitalet, Copenhagen, DK 2100, Denmark|Institut Sainte Catherine, Avignon Cedex 9, 84918, France|Hospices Civils de Lyon HCL, Bron, 69500, France|CHU de Grenoble Hopital Albert Michallon, La Tronche, 38700, France|Centre Hospitalier du Mans, le Mans, 72000, France|CHR Hôpital Calmette, Lille, 59000, France|Hopital Nord, Marseille Cedex 20, 13915, France|CHU de Montpellier - Arnaud de Villeneuve, Montpellier Cedex 5, 34295, France|Institut Curie, Paris, 75005, France|CHU Bordeaux, Pessac, 33604, France|CHRU Hopital de Pontchaillou, Rennes, 35033, France|CHU Nantes, Sain-Herblain, 44800, France|Nouvel Hopital Civil - CHU Strasbourg, Strasbourg cedex, 67091, France|CHU Bretonneau, Tours, 37000, France|Evangelische Lungenklinik Berlin, Berlin, 13125, Germany|Asklepios Klinikum Harburg, Hamburg, 21075, Germany|Thoraxklinik am Universitatsklinikum Heidelberg, Heidelberg, 69126, Germany|Onkologische Schwerpunktpraxis, Heilbronn, 74072, Germany|POIS Sachsen GmbH iG, Leipzig, 04357, Germany|Bethanien Krankenhaus, Moers, 47441, Germany|Klinikum der Universitaet Muenchen, München, 80336, Germany|Oncologianova GmbH, Recklinghausen, 45659, Germany|Universitaetsklinikum Regensburg, Regensburg, 93053, Germany|Queen Mary Hospital, Hong Kong, 999077, Hong Kong|Health Care Global Enterprises pvt Ltd, Bangalore, 560027, India|Artemis Hospital, Gurugram, 122001, India|Tata Medical Center, Kolkata, 700160, India|Tata Memorial Hospital, Mumbai, 400012, India|HCG Manavta Cancer Centre, Nasik, 422002, India|Rajiv Gandhi Cancer Institute and Research Centre, New Delh, 110085, India|Noble Hospital Pvt Ltd, Pune, 411013, India|Bhaktivedanta Hospital & Research Institute, Thane, 411107, India|Soroka University Medical Center, Beersheba, 84101, Israel|Rambam Health Corporation, Haifa, 3109601, Israel|Shaare Zedek Medical Center, Jerusalem, 91031, Israel|Meir Medical Center, Kfar Saba, 44281, Israel|Rabin Medical Center, Petah Tikva, 49100, Israel|Chaim Sheba Medical Center, Ramat Gan, 5262100, Israel|Tel Aviv Sourasky Medical Center, Tel-Aviv, 6423906, Israel|CRO IRCCS Istituto Nazionale Tumori, Aviano, 33081, Italy|Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola, 47014, Italy|Istituto Europeo di Oncologia, Milano, 20141, Italy|Azienda Ospedaliero-Universitaria Di Parma, Parma, 43126, Italy|Ospedale S. Maria Delle Croci, Ravenna, 48121, Italy|Istituto Nazionale Tumori Regina Elena, Roma, 00144, Italy|Policlinico G.B.Rossi, Verona, 37134, Italy|National Hospital Organization Shibukawa Medical Center, Gunma, 377-0280, Japan|Hyogo Cancer Center, Hyogo, 673-8558, Japan|Kanagawa Cancer Center, Kanagawa, 241-8515, Japan|Kobe City Medical Center General Hospital, Kobe City, 650 0047, Japan|Kurume University Hospital, Kurume, 830-0011, Japan|National Hospital Organization Nagoya Medical Center, Nagoya-shi, 460-0001, Japan|Niigata Cancer Center Hospital, Niigata, 951-8566, Japan|Osaka International Cancer Institute, Osaka City, 541 8567, Japan|Shizuoka Cancer Center, Shizuoka, 411 8777, Japan|Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo, 113 8677, Japan|The Cancer Institute Hospital of JFCR, Tokyo, 135 8550, Japan|Ehime University Hospital, Toon-shi, 791-0295, Japan|Wakayama Medical University Hospital, Wakayama, 641 8510, Japan|National Hospital Organization Iwakuni Clinical Center, Yamaguchi, 740-8510, Japan|National Hospital Organization Yamaguchi Ube Medical Center, Yamaguchi, 755-0241, Japan|National Cancer Center, Gyeonggi-do, 10408, Korea, Republic of|CHA Bundang Medical Center, CHA University, Gyeonggi-do, 13496, Korea, Republic of|Seoul National University Bundang Hospital, Gyeonggi-do, 13620, Korea, Republic of|GyeongSang National University Hospital, Gyeongsangnam-do, 52727, Korea, Republic of|Korea University Anam Hospital, Seoul, 02841, Korea, Republic of|Severance Hospital Yonsei University Health System, Seoul, 03722, Korea, Republic of|Asan Medical Center, Seoul, 05505, Korea, Republic of|Samsung Medical Center, Seoul, 06351, Korea, Republic of|The Catholic University of Korea Seoul St Mary s Hospital, Seoul, 06591, Korea, Republic of|University Malaya Medical Centre, Kuala Lumpur, Malaysia|Hospital Tengku Ampuan Afzan, Kuantan, 25100, Malaysia|Beacon Hospital Sdn Bhd, Petaling Jaya, 46050, Malaysia|Subang Jaya Medical Centre, Subang Jaya, 47500, Malaysia|Mount Miriam Cancer Hospital, Tanjung Bungah, 11200, Malaysia|Hospital Civil de Guadalajara Fray Antonio Alcalde, Guadalajara, 44280, Mexico|CIMOVA, Morals Vargas Centro de Investigación SC, Leon, 37000, Mexico|Health Pharma Professional Research, Mexico, 03100, Mexico|Instituto Nacional de Cancerologia, Mexico, 14080, Mexico|Oncologia Integral Satelite, Naucalpan, 53100, Mexico|VUMC Amsterdam, Amsterdam, 1081 HV, Netherlands|Ziekenhuis St Jansdal, Harderwijk, 3844 DG, Netherlands|Erasmus MC, Rotterdam, 3015 GD, Netherlands|Centrum Onkologii im Prof F Lukaszczyka, Bydgoszcz, 85 796, Poland|Uniwersyteckie Centrum Kliniczne, Gdansk, 80 952, Poland|Szpitale Pomorskie Sp z o o, Gdynia, 81 519, Poland|Warminsko-Mazurskie Centrum Chorob Pluc w Olsztynie, Olsztyn, 10-357, Poland|Wielkopolskie Centrum Pulmonologii i Torakochirurgii im. Eugenii i Janusza Zeylandow, Poznan, 60 569, Poland|Private Specialist Hospitals - MedPolonia, Poznan, 60-693, Poland|Narodowy Instytut Onkologii im Marii Sklodowskiej Curie Panstwowy Instytut Badawczy, Warszawa, 02-781, Poland|Uls Santa Maria - Hosp. Pulido Valente, Lisboa, 1769-001, Portugal|Uls Loures Odivelas - Hosp. Loures, Loures, 2674 514, Portugal|Uls Santo Antonio - Hosp. Santo Antonio, Porto, 4099-001, Portugal|Instituto Portugues de Oncologia, Porto, 4200072, Portugal|Pan American Center for Oncology Trials LLC, Rio Piedras, 00917, Puerto Rico|City Clinical Hospital #1, Nalchik, 360000, Russian Federation|Llc, Eurocityclinic, Saint Petersburg, 197022, Russian Federation|Hosp Univ A Coruna, A Coruña, 15006, Spain|Hosp. de La Santa Creu I Sant Pau, Barcelona, 08025, Spain|Hosp. Univ. Quiron Dexeus, Barcelona, 08028, Spain|Hosp Univ Vall D Hebron, Barcelona, 08035, Spain|Hosp Clinic de Barcelona, Barcelona, 08036, Spain|Hosp. Univ. Insular de Gran Canaria, Las Palmas de Gran Canaria, 35016, Spain|Hosp. Gral. Univ. Gregorio Maranon, Madrid, 28007, Spain|Hosp Univ Fund Jimenez Diaz, Madrid, 28040, Spain|Hosp. Univ. 12 de Octubre, Madrid, 28041, Spain|Hosp. Univ. La Paz, Madrid, 28046, Spain|Hosp Univ Hm Sanchinarro, Madrid, 28050, Spain|Hosp. Univ. Pta. de Hierro Majadahonda, Majadahonda, 28222, Spain|Hosp Regional Univ de Malaga, Málaga, 29010, Spain|Clinica Univ. de Navarra, Pamplona, 31008, Spain|Hosp. Virgen Del Rocio, Seville, 41013, Spain|Hosp. Gral. Univ. Valencia, Valencia, 46014, Spain|Hosp. Univ. I Politecni La Fe, Valencia, 46026, Spain|Sahlgrenska Universitetssjukhuset, Goteborg, 413 45, Sweden|Linkoping University Hospital, Linkoping, 581 85, Sweden|Skanes universitetssjukhus, Lund, 221 85, Sweden|Norrlands Universitetssjukhus, Umea, 901 85, Sweden|Akademiska Sjukhuset, Uppsala, 75181, Sweden|Changhua Christian Hospital, Changhua, 500, Taiwan|Kaohsiung Medical University Chung Ho Memorial Hospital, Kaohsiung, 807, Taiwan|Taipei Medical University Shuang Ho Hospital, New Taipei City, 23561, Taiwan|Chung Shan Medical University Hospital, Taichung, 402, Taiwan|Taichung Veterans General Hospital, Taichung, 40705, Taiwan|National Cheng Kung University Hospital, Tainan, 704, Taiwan|National Taiwan University Hospital, Taipei, 100, Taiwan|Adana City Hospital, Adana, 01060, Turkey|Memorial Ankara Hastanesi, Ankara, 06520, Turkey|Gazi University Hospital, Ankara, 06560, Turkey|Ankara Bilkent City Hospital, Ankara, 06800, Turkey|Trakya University Medical Faculty, Edirne, 22030, Turkey|Istanbul University Cerrahpasa Medical Faculty, Istanbul, 34098, Turkey|Bakirkoy Training and Research Hospital, Istanbul, 34147, Turkey|Medipol Mega University Hospital, Istanbul, 34214, Turkey|Goztepe Prof Dr Suleyman Yalcin Sehir Hastanesi, Istanbul, 34722, Turkey|Medical Point, Izmir, 35575, Turkey|Velindre Hospital, Cardiff, CF14 2TL, United Kingdom|Edinburgh Cancer Centre Western General, Edinburgh, EH4 2XU, United Kingdom|UCL Cancer Institute, London, NW1 2PG, United Kingdom|Guys and St Thomas NHS Foundation Trust, London, SE1 9RT, United Kingdom|The Royal Marsden NHS Trust, London, SW3 6JJ, United Kingdom|The Christie Nhs Foundation Trust, Manchester, M20 4BX, United Kingdom","Study Protocol, https://cdn.clinicaltrials.gov/large-docs/95/NCT04988295/Prot_000.pdf|Statistical Analysis Plan, https://cdn.clinicaltrials.gov/large-docs/95/NCT04988295/SAP_001.pdf"
